Fig. 5From: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysisForest plots of progressive-free survival (PFS). A Forest plots of PFS for Nivolumab alone or in combination with Ipilimumab; CI, confidence interval; B Forest plots of PFS for Nivolumab alone or in combination with Ipilimumab after removing one study; CI, confidence intervalBack to article page